Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2010

01.06.2010 | Short Research Paper

Detection of adverse drug reactions through the minimum basic data set

verfasst von: Antonio Salmerón-García, José Cabeza Barrera, Maria José Vergara Pavón, Eva Román Márquez, Sol Cortés de Miguel, Inmaculada Vallejo-Rodríguez, Susana Raya García, Emilia Casado Fernández

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective To analyze adverse drug reaction (ADR) detection using the Minimum Basic Data Set (MBDS) at hospital discharge and to compare the ADR reporting rate to the Pharmacovigilance Referral Centre with other similar hospitals that do not use this reporting system. Setting 650-bed University Hospital serving a population of 294,000 inhabitants in Spain. Method: A retrospective descriptive study was conducted between January 2006 and December 2007. All reports of ADRs gathered in MBDS (a tool that encodes all administrative and clinical information generated for each patient during a hospitalization episode) with International Classification Disease codes between E930 and E949.9 were analyzed to assess the appropriateness of their referral to the pharmacovigilance centre. Finally, we compared our reporting rate with other hospitals that do not use this system for ADR identification. Main outcome measure The incidence of ADRs detected in hospitalized patients and the reporting rate (per thousand inhabitants) to the referral pharmacovigilance centre using the Yellow Card system. Results: Out of 43,282 hospital discharges, 386 ADR were recorded (0.89% of hospitalized patients). The mean (±SD) age of patients with reported ADR was 61.9 years (±19.2), median age was 65 years, and 55.2% were female. The Department of Pharmacy reported 276 (71.5%) of ADR using the Yellow Card system. The most frequently reported drugs were anti-cancer agents (42.5%) and cardiovascular drugs (23.8%), with a high frequency of digitalis glycosides (18.4%). ADR were most frequently recorded by the Departments of Oncology (41.7%) and Internal Medicine (17.9%). Conclusion The MBDS is a useful and accessible instrument to determine the incidence of ADR in a hospital, resulting in the notification of severe events that might otherwise not be reported. Its use also improves identification of the main drugs responsible for ADR and of the patient populations at greatest risk, facilitating the implementation of alert systems and the development of prevention and detection strategies.
Literatur
1.
Zurück zum Zitat The World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal products. Geneva: WHO; 2002. ISBN 92 4 1590157. The World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal products. Geneva: WHO; 2002. ISBN 92 4 1590157.
2.
Zurück zum Zitat Moore N, Montero D, Coulson R, de Abajo FJ, Kreft-Jais C, Biron A, et al. Communication in drug surveillance. Pharmacoepidemiol Drug Saf. 1994;3:151–5.CrossRef Moore N, Montero D, Coulson R, de Abajo FJ, Kreft-Jais C, Biron A, et al. Communication in drug surveillance. Pharmacoepidemiol Drug Saf. 1994;3:151–5.CrossRef
3.
Zurück zum Zitat Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol. 2007;7:9.CrossRefPubMed Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol. 2007;7:9.CrossRefPubMed
4.
Zurück zum Zitat International Drug Monitoring: The Role of National Centres. World Health Organization. Technical Report Series 498. Geneva: World Health Organization; 1972. International Drug Monitoring: The Role of National Centres. World Health Organization. Technical Report Series 498. Geneva: World Health Organization; 1972.
6.
Zurück zum Zitat The Uppsala Monitoring Centre (the UMC), WHO Collaborating Centre for International Drug Monitoring, Uppsala (homepage on the Internet); 2009 (cited 2009 May 30). http://www.who-umc.org. The Uppsala Monitoring Centre (the UMC), WHO Collaborating Centre for International Drug Monitoring, Uppsala (homepage on the Internet); 2009 (cited 2009 May 30). http://​www.​who-umc.​org.
7.
Zurück zum Zitat Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernández-Díaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30:1073–82.CrossRefPubMed Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernández-Díaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30:1073–82.CrossRefPubMed
8.
Zurück zum Zitat Van Grootheest AC, van Puijenbroek EP, den Berg LT. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:205–10.CrossRefPubMed Van Grootheest AC, van Puijenbroek EP, den Berg LT. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:205–10.CrossRefPubMed
9.
Zurück zum Zitat Ahmad SR, Freiman JP, Graham DJ, Nelson RC. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiol Drug Saf. 1996;5:1–7.PubMed Ahmad SR, Freiman JP, Graham DJ, Nelson RC. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiol Drug Saf. 1996;5:1–7.PubMed
10.
Zurück zum Zitat Van Grootheest K, Olsson S, Couper M, den Berg L. Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004;13:457–64.CrossRefPubMed Van Grootheest K, Olsson S, Couper M, den Berg L. Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004;13:457–64.CrossRefPubMed
11.
Zurück zum Zitat Ministerial Order of 6 September 1984 establishing the obligation for a hospital discharge report for all patients. B.O.E. no 221 of 14 September; 1984. Ministerial Order of 6 September 1984 establishing the obligation for a hospital discharge report for all patients. B.O.E. no 221 of 14 September; 1984.
12.
Zurück zum Zitat Torelló J. Role of the MBDS in drug surveillance. Advantages and limitations of an underused tool. Arch Fac Med Zaragoza. 2001;41(Supll I):24–8. Torelló J. Role of the MBDS in drug surveillance. Advantages and limitations of an underused tool. Arch Fac Med Zaragoza. 2001;41(Supll I):24–8.
13.
Zurück zum Zitat Sotoca JM, Corominas N, Codina C, Ribas J. Efectos adversos a medicamentos detectados a través del conjunto mínimo básico de datos de las altas hospitalarias. (Adverse drug-related effects detected across the minimaum basic data set at the hospital discharges). El Farmacéutico Hospitales. 2006;174:5–7. Sotoca JM, Corominas N, Codina C, Ribas J. Efectos adversos a medicamentos detectados a través del conjunto mínimo básico de datos de las altas hospitalarias. (Adverse drug-related effects detected across the minimaum basic data set at the hospital discharges). El Farmacéutico Hospitales. 2006;174:5–7.
14.
Zurück zum Zitat Sánchez Muñoz LA, Castiella Herrero J, Sanjuán Portugal FJ, Naya Manchado J, Alfaro Alfaro MJ. Usefulness of MBDS in detection of adverse drug events. An Med Interna. 2007;24:113–9.PubMed Sánchez Muñoz LA, Castiella Herrero J, Sanjuán Portugal FJ, Naya Manchado J, Alfaro Alfaro MJ. Usefulness of MBDS in detection of adverse drug events. An Med Interna. 2007;24:113–9.PubMed
15.
Zurück zum Zitat Corral Baena S, Guerrero Aznar MD, Beltrán García M, Salas Turrens J. Use of MBDS as a tool for the detection of drug-related adverse events. Farm Hosp. 2004;28:258–65.PubMed Corral Baena S, Guerrero Aznar MD, Beltrán García M, Salas Turrens J. Use of MBDS as a tool for the detection of drug-related adverse events. Farm Hosp. 2004;28:258–65.PubMed
16.
Zurück zum Zitat Leonard CE, Haynes K, Localio AR, Hennessy S, Tjia J, Cohen A, et al. Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. J Clin Epidemiol. 2008;61:561–71.CrossRefPubMed Leonard CE, Haynes K, Localio AR, Hennessy S, Tjia J, Cohen A, et al. Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. J Clin Epidemiol. 2008;61:561–71.CrossRefPubMed
17.
Zurück zum Zitat Castillo JR, Merino N, Bejarano MD, Domínguez JC, Fernández G, García J, et al. Results of the program of spontaneous notification of adverse reactions in Andalusia. Year 2006. Alert Drug Surveill 2007; 36:13–16. Castillo JR, Merino N, Bejarano MD, Domínguez JC, Fernández G, García J, et al. Results of the program of spontaneous notification of adverse reactions in Andalusia. Year 2006. Alert Drug Surveill 2007; 36:13–16.
18.
Zurück zum Zitat Heeley E, Riley J, Layton D, Wilton L, Shakir S. Prescription event monitoring and reporting of adverse drug reactions. Lancet. 2001;358:1872–3.CrossRefPubMed Heeley E, Riley J, Layton D, Wilton L, Shakir S. Prescription event monitoring and reporting of adverse drug reactions. Lancet. 2001;358:1872–3.CrossRefPubMed
20.
Zurück zum Zitat Colville R, Laing J, Murison M. Coding plastic surgery operations: an audit of performance using OPCS-4. Br J Plast Surg. 2000;53:420–2.CrossRefPubMed Colville R, Laing J, Murison M. Coding plastic surgery operations: an audit of performance using OPCS-4. Br J Plast Surg. 2000;53:420–2.CrossRefPubMed
21.
Zurück zum Zitat Waller P, Shaw M, Ho D, Shakir S, Ebrahim S. Hospital admissions for drug induced disorders in England: a study using the Hospital Episodes Statistics (HES) database. Br J Clin Pharmacol. 2004;59:213–9.CrossRef Waller P, Shaw M, Ho D, Shakir S, Ebrahim S. Hospital admissions for drug induced disorders in England: a study using the Hospital Episodes Statistics (HES) database. Br J Clin Pharmacol. 2004;59:213–9.CrossRef
22.
Zurück zum Zitat Budnitz D, Pollock D, Weidenbach K, et al. National Surveillance of emergency department visits for outpatients adverse drug events. JAMA. 2006;296:1858–66.CrossRefPubMed Budnitz D, Pollock D, Weidenbach K, et al. National Surveillance of emergency department visits for outpatients adverse drug events. JAMA. 2006;296:1858–66.CrossRefPubMed
23.
Zurück zum Zitat Burgess CL, Holman CD, Satti AG. Adverse drug reactions in older Australians, 1981–2002. Med J Aust. 2005;182:267–70.PubMed Burgess CL, Holman CD, Satti AG. Adverse drug reactions in older Australians, 1981–2002. Med J Aust. 2005;182:267–70.PubMed
24.
Zurück zum Zitat Caamano F, Pedone C, Zuccala G, Carbonin P. Sociodemographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch Gerontol Geriatr. 2005;40:45–52.CrossRefPubMed Caamano F, Pedone C, Zuccala G, Carbonin P. Sociodemographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch Gerontol Geriatr. 2005;40:45–52.CrossRefPubMed
25.
Zurück zum Zitat Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.CrossRefPubMed Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.CrossRefPubMed
26.
Zurück zum Zitat Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.CrossRefPubMed Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.CrossRefPubMed
27.
Zurück zum Zitat Kongkaew C, Noyce P, Ashcroft D. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42:1017–25.CrossRefPubMed Kongkaew C, Noyce P, Ashcroft D. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42:1017–25.CrossRefPubMed
28.
Zurück zum Zitat Romero del Barco R, Ferrando R, Soler E, Blázquez MA, González A, Vilella M. Detection and analysis of adverse drug-related events across the minimum basic data set Atención Farm. Eur J Clin Pharm. 2008;10:143–6. Romero del Barco R, Ferrando R, Soler E, Blázquez MA, González A, Vilella M. Detection and analysis of adverse drug-related events across the minimum basic data set Atención Farm. Eur J Clin Pharm. 2008;10:143–6.
29.
Zurück zum Zitat Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.CrossRefPubMed Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.CrossRefPubMed
30.
Zurück zum Zitat Wright R, Handler SM, Ruby C, Hanlon JT. Update on drug-related problems in the elderly. Am J Geriatr Pharmacother. 2006;4:78–84.CrossRef Wright R, Handler SM, Ruby C, Hanlon JT. Update on drug-related problems in the elderly. Am J Geriatr Pharmacother. 2006;4:78–84.CrossRef
31.
Zurück zum Zitat Brøsen K. Sex differences in pharmacology. Ugeskr Laeger. 2007;169:2408–11.PubMed Brøsen K. Sex differences in pharmacology. Ugeskr Laeger. 2007;169:2408–11.PubMed
32.
Zurück zum Zitat Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1–10.CrossRefPubMed Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1–10.CrossRefPubMed
Metadaten
Titel
Detection of adverse drug reactions through the minimum basic data set
verfasst von
Antonio Salmerón-García
José Cabeza Barrera
Maria José Vergara Pavón
Eva Román Márquez
Sol Cortés de Miguel
Inmaculada Vallejo-Rodríguez
Susana Raya García
Emilia Casado Fernández
Publikationsdatum
01.06.2010
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2010
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9372-2

Weitere Artikel der Ausgabe 3/2010

International Journal of Clinical Pharmacy 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.